IL1B and inflammation: Thus, we conclude that syndecan-4 had limited clinical value as a circulating biomarker of cardiac inflammation and that immunomodulating therapies targeting IL-1β likely will affect the molecular processes that shed syndecan-4 ectodomains play locally in cardiac tissue.